14-month Study for People With Type 2 Diabetes and Obesity

Written By Patrick Smith

Are you living with type 2 diabetes and obesity and are taking metformin or an SGLT-2 inhibitor (such as Jardiance, Farxiga, or Invokana), or both?

If so, you may be eligible to participate in a clinical research study assessing an investigational GLP-1 medicine called zenagamtide.

ABOUT THE STUDY

This is a Phase 3 study assessing how zenagamtide affects blood sugar levels and body weight.

WHO MAY QUALIFY?

You may be eligible to participate if you meet all the following:

  • Age 18 years or older

  • Have type 2 diabetes

  • Currently taking metformin, an SGLT-2 inhibitor (such as Jardiance, Farxiga, or Invokana), or both

  • HbA1c between 7.5% and 10.5%

  • BMI of 30 or higher (classified as obesity)

  • Have not used any GLP-1-based medication — including pills or injections (such as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, or Foundayo) — within the past year

  • Have never had surgery for treatment of obesity

INTERESTED IN LEARNING MORE?

Click below to complete a short questionnaire to see if you may be eligible.

SEE IF YOU QUALIFY


Study Sponsor: Novo Nordisk


Patrick Smith
Previous

44-week Study for People With Type 2 Diabetes Who Are Normal Weight, Overweight, or Obese
Next

2-year Study for People With Type 2 Diabetes and Overweight or Obesity